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1 1 0 Chapter 9
Summary
Subject of this thesis is the variation in airway diameter. In patients with
obstructive airways diseases like asthma and chronic obstructive pulmonary disease
(COPD), the airway diameter can change markedly between days and within days and
there can be an excessive decrease in lung function over a longer period of time when
cornpared to the course over time in healthy individuals. Decrease in airway diameter
can be accompanied by symptoms like breathlessness. cough, wheezing, chest
tightness, and/or breathlessness on exertion. Management of asthma and COPD is
generally directed towards the abnormal physiology and its sequelae. The main goals
in managing asthma and COPD are: 1) to prevent or decrease airway nanowing, 2) to
rninimize the maximal level of airway narrowing,3) to prevent or minimize increase
in airflow limitation over time, and 4) to minimize symptoms.
Chapter 2 and 3 deal with the key lung function parameters of obstructive
airways diseases: airways obstruction, bronchodilator responsiveness and
bronchoconstrictor responsiveness. Long tenn effects of treatrnent on lung function,
bronchoconstrictor responsiveness and symptoms are evaluated in chapter 4. The role
of peak expiratory flow (PEF) measurements in disease management is discussed in
chapter 5, 6, and 7, and finally, in chapter 8, the effects of a transdermally
administrated anticholinergic agent on symptoms, iung function and
bronchoconstrictor responsiveness to methacholine are described.
Chupter 2
In this chapter, the relation between bronchodilator and bronchoconstrictor
responsiveness is discussed, as well as their supposed interchangeabil ity in an
epidemiological setting. Bronchodilator responsiveness has been considered the
physiological opposite of bronchoconstrictor responsiveness in patients with
obstructive airways diseases. As a consequence, bronchoconstrictor responsiveness
tests have sometimes been replaced by bronchodilator responsiveness tests in
epidemiological studies, especially in patients with obstructive airways. in order to
prevent the risk of excessive airway narrowing. However. it can be questioned
whether the outcome of both tests can be interchanged.
In this population based study, cumulative dose response curves were used for
both tests. This allowed us to corelate the sensitivity to the constrictor (histamine)
not onll 'with the maximal airway dilatation (which is commonly perfbrmed) but also
with the sensitivity to the bronchodilator (terbutaline).
Results show that bronchodilator and bronchoconstrictor responsiveness were
not closely comelated, not even in a selection of subjects with airways obstruction.
Patients with a bronchodilator response were not more likely to exhibit a
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bronchoconstrictor response and the other way around. In a subgroup ofsubjects with
a bronchoconstrictor response, sensitivity to histamine was correlated with sensitivity
to terbutaline but not with the maximal airways response to terbutaline. From this
study it can be stated that, in epidemiological research, the outcome of a
bronchodilator test is not an accurate basis for the classification ofa person as having
increased responsiveness to a bronchoconstrictor. Bronchoconstrictor responsiveness
and bronchodilator responsiveness are two different phenotypic markers that are not
interchangeable in epidemiological studies.
Chapter 3
Hyperresponsiveness to a bronchoconstrictor is associated with airway
inflammation in asthma. Bronchoconstrictor responsiveness can be tested with
different stimuli such as methacholine (MCh) and adenosine 5'-monophosphate
(AI\P). MCh acts directly on airway smooth muscle and AMP acts directly on mast
cells in the airway wall, resulting in release of mediators such as histamine,
prostaglandines and leukotrienes. It has been shown before that inhaled
corlicosteroids improve bronchoconstrictor responsiveness to AMP more than to
MCh. Furtherrnore, it is known that the long-acting B2-agonist salmeterol protects
against MCh induced bronchoconstriction equally well as the anti-inflammatory drug
fluticasone. However, there were no data on the protective effect of salmeterol against
AMP in comparison with fluticasone.
This study showed that bronchoconstrictor responsiveness to AMP was improved
significantly more by maintenance treatment with fluticasone compared to salmeterol,
12 hours after the last dose (i.e. the moment at which the next dose should be taken).
Salmeterol had a comparable protective affect against AMP and against MCh.
The larger protective effect of fluticasone to AMP compared to salmeterol might be
explained by the influence of inhaled cofticosteroids on the number and activity of the
mast cells. The comparable protective effect of salmeterol against MCh and AMP
might be explained by the fact that salmeterol is a very potent functional antagonist.
Under treatment with salmeterol, a larger dose of a bronchoconstrictor is required to
elicit a 20Yo fall in FEV 1 .
In former studies, bronchoconstrictor esponsiveness has been used as a major
treatment-effect parameter in patients with asthma. With the conventional effect
parameters (including bronchoconstrictor responsiveness to MCh) a comparable
asthma controlling effect was observed fbr fluticasone and salmeterol. Our findings
suggest that AMP challenge can serve better to discern the anti-inflammatory effects
of inhaled corticosteroids from the functional antagonistic effects of long acting B2-
agonists in bronchoprovocation tests.
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Chapter 4
Treatment with inhaled corticosteroids is widely used in management of patients
with obstructive airways diseases. It has been shown that inhaled cotlicosteroids
improve both airway diameter and bronchoconstrictor responsiveness. Until now,
little is known about the duration of these improvements. In this chapter the long-term
effects of treatment with inhaled beclomethasone in combination with terbutaline
were evaluated in patients with increased bronchoconstrictor responsiveness and
airways obstruction. In responders, the initial improvement in lung function, bronchial
hyperresponsiveness and symptoms were well maintained over a total period of five
years. Additionally, there was no accelerated fall in lung function in these patients
compared to the general population'
Patients who did not respond sufficiently to beclornethasone 800 pg with respect to
the FEVr showed no statistically significant improvernent in FEVr,
bronchoconstrictor responsiveness, PEF, and symptoms after increasing the dose of
BDP, although there was a trend toward improvement for all of these parameters'
Because of the small number of nine insufficient responders' we could not draw fitm
conclusions from these results.
our study stresses the importance of continuous long-tetm treatment with inlaled
corticosteroids in patients with bronchial hypenesponsiveness and obstructive
airways diseases.
Chapter 5
The role of PEF measurements in monitoring obstructive airways diseases has
gained considerable impoftance since the appearance of the asthma treatment
guidelines. Therefore, it is of great imporlance to test the reliability of PEF values
obtained with frequently used PEF meters. In this study, we examined PEF values
measured with peak flow meters that had been used more than 2,000 times over five
years. We compared the PEF values of these (old) meters to values measured with
identical new ones. In addition, accuracy of both old and new meters was assessed by
pneumotachograPhY.
we found a statistically significant, but for most patients clinically irrelevant
difference in mean PEF value between old mini-wright PEF tneters and identical new
meters. However, differences on an individual basis can be large. We concluded from
this study that intensive and prolonged use of PEF meters does not lead to unreliable
mean PEF values in long-tenl studies, and that replacement of PEF meters in disease
monitoring or in long-term studies should be avoided, given the wide limits of
agreement, except in case of obvious malfunction'
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Chapter 6
Home PEF measurements have become the cornerstone of self-management plans.
Treatment categories are defined on the basis of cut-off values of PEF, usually in
three zones: green, yellow, and red. Entry into the lower PEF zones necessitates
increased treatment. Unforlunatelv. to date the PEF cut-off values have been
arbitrarily chosen.
In this chapter rve evaluated the impact of advised PEF cut-off values on asthma
treatn-rent in clinically stable patients with increased bronchoconstrictor
responsiveness and with a bronchodilator response. We have specifically focused on
the prevalence of overtreatment in relation to these cut-off values. We also
investigated how effects on overtreatment changed when using different criteria for
the personal  bcst  va lue.
Strict adherence to advised cut-off values (80 and 60Yo of the personal best or of
the predicted value) leads to a high prevalence of overtreatment in asthmatics who
were treated with inhaled corticosteroids. Up to 30oh of clinically stable patients
would cross into the red zone at least once a yeat when personal best is the
denominator and when it has not been limited to a defined time of the day or to
defined prior bronchodilator use. A general lowering of cut-off values would
certainly temper oveftreatment, but is a rather crude solution and could lead to
dangerous undertreatment. A better solution to our opinion is to relate measured peak
flows to personal best values measured at the same time of the day and under the
same conditions. It is obvious that when morning PEF values before the use of a
bronchodilator (r,rsually the lowest day value) are related to a personal best value
measured in the evening after a bronchodilator (usually the highest day value) this
will lead to flequent crossing into the yellow or red zones.
Moming PEF before medication seems to be the most useful parameter in self-
management plans because this value is least influenced by variable prior use of
bronchodilators.
We have focused entirely on overteatrnent whereas the guidelines have been
perceived (but not tested) in an era ofconcern about undeftreatment. The final choice
of the right cut-off value should be based on minimising both overtreatment and
undertreatment. From the perspective of ovefireatment, we suggest to use the moming
value of PEF, expressed as o/o of the morning personal best value, at two consecutive
days, being 50% for reaching the red zone and -l\oh for reaching the yellow zone.
These morning PEF measurements should be performed before use of
bronchodilators.
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Chapter 7
Recent studies have shown that PEF indices like morning PEF and PEF variability
corelate well with bronchoconstrictor responsiveness. cross-sectionally. Since
bronchoconstrictor responsiveness is an imporlant treatment parameter in asthmatic
patients it would be desirable to have a PEF index that correlates well with
bronchoconstrictor responsiveness, longitudinally.
ln this 2-year study we evaluated which PEF index conelated best with
bronchoconstrictor responsiveness longitudinally in patients with established
increased bronchoconstrictor responsiveness, who started treatment with
bronchodilators only or in combination with inhaled cofticosteroids.
Changes in PEF indices reflecting bronchodilator response and within day
variability correlated best with changes in bronchial hyperresponsiveness. but median
rho values were low and varied only between -0.33 and -0.50. These results applied to
the group of asthmatic patients, treated with inhaled cofticosteroids and
bronchodilators. In a similar group of patients who were treated with bronchodilators
only, the median correlation coefficients were even lower.
Since it has been shown that PEF readings are inaccLrrate in certain flow ranges, we
had hoped that the generally weak correlation coefficients between PEF indices and
BHR would improve aftel correcting the PEF data for this inaccuracy. Unfortunately,
there were no changes in corelation coefficients of any importance.
Because we only found weak to moderate conelations between PEF indices and
bronchoconstrictor responsiveness longitudinally, we concluded that follow up of
PEF indices are not a good proxy for changes in bronchoconstrictor responsiveness.
Chupter I
Long-acting B2-agonists have been developed to increase the duration oftreatment
effect. This is especially useful during the night when lung function values are low.
Up to now there are no long-acting anticholinergic agents registered for patient use. It
seems to be worthwhile to investigate transdermal delivery of bronchodilators
because it produces sustained. constant and controlled plasma drug concentrations.
Moreover, transdermal delivery might be accompanied by reduction in dose
frequency, and thus increase patient compliance. In this chapter we combined two
consecutive double-blind placebo-controlled cross-over studies oll transdemral
scopolamine (Scopoderm@ TTS patches), an anticholinergic agent marketed for the
prevention of nausea and vomiting associated with nrotion sickness.
In the first study, no significant effects of transdermal scopolamine on pulmonary
function and symptoms were found. Nevertheless, there was a decrease in use of
bronchodilators and a larger decrease in symptoms during daytime with scopolamine
compared to placebo, though not statistically significant. The lack of clinical effect
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was not due to inadequate uptake of scopolamine from the patch as shown by the
urinary and plasma levels of scopolamine, but could be due to sub-therapeutic doses.
The second study, however, demonstrated that a double dose of scopolamine was not
able to improve clinical parameters fur1her. There also was no significant protection
of scopolamine to the responsiveness to methacholine. Unfortunately, the plasma
levels of free scopolamine obtained with the two patches tumed out to be sufficient to
trigger a nurnber of r,rnwanted anticholinergic side effects, but were still too low to
reaclr therapeutic levels at the cholinergic receptor sites in the lungs.
Conclus ions
- Bronchoconstrictor responsiveness and bronchodilator responsiveness are two
different phenotypic markers that are not interchangeable in epiderniological
studies (chapter 2).
- In subjects with a bronchoconstrictor response, there is a weak but significant
positive correlation between the sensitivity to the bronchoconstrictor histamine
and the bronchodilator terbutaline (chapter 2).
- AMP challenges can serve better than MCh challenges to discern the anti-
inflammatory effects of inialed corticosteroids from the functional antagonistic
effects of long acting B2-agonists in bronchoprovocation tests (chapter 3).
- Mean initial improvements in lung function, bronchial hyperresponsiveness and
symptoms are well maintained over at least five years in a group of patients who
are treated with beclomethasone in combination with terbutaline (chapter 4).
- Intensive and prolonged use of mini-Wright PEF meters does not lead to
unreliable mean PEF values in long term studies. Replacement in disease
monitoring or in long-term studies shor"rld be avoided. given the wide l imits of
agreement (chapter 5).
- Currently advised PEF cut-off values in clinically stable asthmatics lead to
overtreatment in substantial nunrbers ofpatients (chapter 6).
- Although PEF indices have been proven to be useful in self-management plans,
they are not suitable as a proxy lbr bronchoconstrictor responsiveness
longitudinally (chapter 7).
- fhe level of f lee scopolamine (obtained r.r, ith two Scopoclerrt TTS patches) is
sufficient to trigger a number of unwanted anticholinergic side effects. but is too
low to reach therapeuticaily efl-ective levels at the cholinergic receptor sites in the
lungs (chapter 8).
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Recommendations for future research
In recent years, research on the management of obstructive airways diseases has
made considerable progress. An important step forward was the introduction of
inhaled corticosteroids. These drugs have become the mainstay of treatment regimes
in patients with asthma. Another step was the introduction of self-management plans.
With these plans, patients (especially asthmatics) gain more insight in their disease,
and according to specific schemes they are encouraged to adjust their medication,
based on defined criteria regarding symptoms and PEF values. The introduction of
these plans could be labelled a little premature since the criteria on which treatment
adjustments were based had not been studied properly. On the other hand, since they
were written down, these plans have triggered off research to better document the use
of PEF meters at home and their value in disease management (chapter 5 and 6).
Optimal individual dose of inhaled corticosteroids
Asthma is a chronic disease and it is, therefore, insufficient to be satisfied with
short term improvement only. Improvements in short-term studies should
subsequently be evaluated in studies with a long-term follow-up. Our study showed
that treatment with inhaled corticosteroids in combination with B2-agonists improved
lung function, bronchoconstrictor response, and symptoms, and that the mean initial
improvement of these parameters was well maintained over at least five years in
patients with obstructive airways diseases (chapter 4). The results of this study
applied to the group as a whole. However, for clinical practice and in self-
management programs it is important to determine the optirnal individual dose in
order to avoid both underlreatment and overtreatment. Further studies are necessary to
hnd a practicable strategy for adjustment of treatment. For example, one could start
from the best possible personal situation with regard to the effect pararneters. From
that point, the dose of inhaled corticosteroids should be decreased without allowing
deterioration of these parameters. An important issue of future research should be to
find the most suitable parameters to predict deterioration in time. ldeally these
parameters should also assess whether the physiology of the airway has normalized,
i.e. the cluonic sequelae of the inflammatory process.
Selection and deJinition of parameters
The choice and definition of the treatment-effect parameters and parameters of
disease outcome is crucial in management plans. Many parameters of lung function,
symptoms and bronchoconstrictor responsiveness are associated with obstructive
airways diseases and most of these are not mutually interchangeable so that they seem
to have their own ulace in relation to the disease. It would be preferable to find/select
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only a few parameters, or a combination of parameters, that correiate best with the
severity of the disease.
Effect parometers
In current guidelines on asthna management, adjustments of the level of anti-
inflammatory treatrnent is based on changes in symptoms, ft"rng function parameters
and number or severity of exacerbations. Recently it has been shown that adjustment
of the level of anti-inflammatory therapy should also be based on the outcome of
repeated bronchoconstrictor tests.
To date, bronchoscopy (biopsy and bronchoalveolar lavage) is the golden standard
to assess the inflamnatory state of the airways. It is obvious that this investigation is
not suitable in monitoring patients. Bronchoconstrictor tests are less invasive and are
associated with inflammation. Unfortunately, these tests do also have some
disadvantages. They can only be performed in a clinical setting because of possible
excessive airway narrowing and possible side effects. Patients with cardiovascular
diseases and/or a baseline FEVl less than I L are usually excluded from these tests.
Because of these disadvantages, it would be favourable to find a more suitable
parameter to reflect inflammation. Our study showed that a bronchoconstrictor test
can not be replaced by a bronchodilator test (chapter 3) and that none of the known
PEF indices can be used as a proxy for bronchoconstrictor responsiveness.
longitudinally (chapter 7). Future research might be able to find a parameter eflecting
airway inf'lanurration which can be easily obtained and interpreted. preferably in the
home setting in that this parameter can also be used in self-management plans. One
might think of a marker of airway inflammation in blood or sputum or exhaled air
rvhich could be measured at home by using reagent strips or instruments for readings.
as is cunently being used in diabetes self-measurements.
D is e as e outc o nle parctme te r s
Examples of disease outcome parameters that are presently used include lung
function parameters (prevention of an excessive decline in lung function and
prevention of the developnrent of irrevelsible airways obstruction),
bronchoconstrictor responsiveness (improvement in blonchoconstrictor
responsiveness as a proxy for the inflammatory state), number and severity of
exacerbations and quality of life. One can argue whether one should aim for
improvement in bronchoconstrictor response. Improvement in bronchoconstrictor
responsiveness does not inevitably reflect improvement of inflammation. A similar
improvement in bronchoconstrictor responsiveness to the same agonist, due to
different treatments can be based on different underlying mechanisms, such as
reduction in airway wall thickness, number and activity of inflammatory cells, or
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airway smooth muscle dilatation (chapter 3). Further studies are necessary to
investigate whether the same improvement in lung function, symptoms, number of
exacerbations and bronchoconstrictor response, reached by different treatment
regimens (long-acting bronchodilators or anti-inflammatory treatment) would have a
similar disease outcome on the long term. It is likely that treatment aiming at
improvement of airway inflammation will be preferable. This study showed that AMP
challenges compared to MCh challenges can serve better to discern the anti-
inflammatory effects of inhaled corticosteroids from the functional antagonistic
effects of long-acting B2-agonists in bronchoprovocation tests (chapter 3). Future
long-term studies preferably should use both MCh and AMP challenges to investigate
whether these tests have different nredictive values with resard to disease outcome on
the long term.
Transdermsl delivery of anticltolinergics
This stucly showecl that two Scopoderm@ TTS patches did not improve lung
function and symptorns and had no protective effect against the bronchoconstrictor
methacholine (chapter 8). Further research on transdermal application of
anticholinergics should use a dmg with a higher binding affinity to the muscarinic
receptor sites in the lungs than to those in the central nervous system, responsible for
the side effects. However. the need for transdermally administration in order to have a
long duration of action reduces since long-acting anticholinergics with brondilation
up to 48 hours after a single dose have entered phase 3 studies with promising results.
At this point in time, it is a matter of speculation whether these long-acting
anticholinergics will have a role in asthma, for instance in severe asthma and for
patients with a fixed obstructive component despite the use of B2-agonists.
l
